Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Schwartz

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|March 23, 2010
IL-4 and TGF-beta 1 counterbalance one another while regulating mast cell homeostasisMatthew R Macey, Jamie L Sturgill, Johanna K Morales, et al.
Annals of Surgery|June 27, 2008
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resectionItaru Endo, Mithat Gonen, Adam C Yopp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancerWilliam Kevin Kelly, Owen A O'Connor, Lee M Krug, et al.
Blood|November 17, 2017
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphomaJennifer E Amengual, Renee Lichtenstein, Jennifer Lue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerMichael J Morris, Neeta Pandit-Taskar, Jorge Carrasquillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancerMichael J Morris, Chaitanya R Divgi, Neeta Pandit-Taskar, et al.
JCO Precision Oncology|April 18, 2024
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working GroupErica C Nakajima, Amber Simpson, Jan Bogaerts, et al.
Frontiers in Oncology|March 20, 2013
Future vision for the quality assurance of oncology clinical trialsThomas J Fitzgerald, Maryann Bishop-Jodoin, Walter R Bosch, et al.
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2018
The Importance of Imaging in Radiation Oncology for National Clinical Trials Network ProtocolsThomas J FitzGerald, Maryann Bishop-Jodoin, Fran Laurie, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Journal of Immunology (Baltimore, Md. : 1950)|March 23, 2010
IL-4 and TGF-beta 1 counterbalance one another while regulating mast cell homeostasisMatthew R Macey, Jamie L Sturgill, Johanna K Morales, et al.
Annals of Surgery|June 27, 2008
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resectionItaru Endo, Mithat Gonen, Adam C Yopp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancerWilliam Kevin Kelly, Owen A O'Connor, Lee M Krug, et al.
Blood|November 17, 2017
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphomaJennifer E Amengual, Renee Lichtenstein, Jennifer Lue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerMichael J Morris, Neeta Pandit-Taskar, Jorge Carrasquillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancerMichael J Morris, Chaitanya R Divgi, Neeta Pandit-Taskar, et al.
JCO Precision Oncology|April 18, 2024
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working GroupErica C Nakajima, Amber Simpson, Jan Bogaerts, et al.
Frontiers in Oncology|March 20, 2013
Future vision for the quality assurance of oncology clinical trialsThomas J Fitzgerald, Maryann Bishop-Jodoin, Walter R Bosch, et al.
The Lancet. Oncology|December 26, 2017
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trialOwen A O'Connor, Jennifer K Lue, Ahmed Sawas, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2018
The Importance of Imaging in Radiation Oncology for National Clinical Trials Network ProtocolsThomas J FitzGerald, Maryann Bishop-Jodoin, Fran Laurie, et al.
Pageof 9